Clinical Trials Browser

Phase 2 × UNKNOWN × Rituximab × Clear all

NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Phase 2 Unknown

Lymphoma, Recurrence

NCT04425824 2020-06-16

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse